|
Goldman Sachs downgrades Glaxo to "sell"
Forbes AP , 05.31.11, 10:57 AM EDT WASHINGTON — A Goldman Sacks analyst says GlaxoSmithKline's stock is overvalued as the British drugmaker prepares to face lower sales of its best-selling product, the asthma inhaler Advair. Goldman analyst Mark Beards notes … Goldman Downgrades GSK as Growth Won't Support Valuation Goldman Sachs downgrades Glaxo to "sell" |
View full post on asthma – Google News